PMID- 11011335
OWN - NLM
STAT- MEDLINE
DCOM- 20001102
LR  - 20151119
IS  - 1097-6744 (Electronic)
IS  - 0002-8703 (Linking)
VI  - 140
IP  - 4
DP  - 2000 Oct
TI  - Renal endothelin in heart failure and its relation to sodium excretion.
PG  - 617-22
AB  - BACKGROUND: Recent studies have shown that endothelin-1 (ET-1) antagonists 
      increase sodium excretion and improve renal blood flow in experimental heart 
      failure (HF). However, despite a number of investigations that have reported a 
      significant increase in ET-1 plasma levels in patients with HF, it is still not 
      known whether increased renal synthesis and urinary excretion of ET-1 occur. Our 
      aim was to investigate renal ET-1 formation and its relation to sodium excretion 
      in patients with HF. METHODS: One hundred forty-seven patients with HF, 
      subdivided according to New York Heart Association (NYHA) functional classes, and 
      28 healthy controls were studied. ET-1 and big ET-1 were measured in plasma and 
      in 24-hour urine by radioimmunoassay. Atrial and brain natriuretic peptide, 
      arginine vasopressin, plasma renin activity, and hemodynamic variables were also 
      investigated. RESULTS: Urinary ET-1 excretion was already increased in NYHA class 
      II patients (P <.001 vs controls), whereas plasma ET-1 increased only in NYHA 
      class III and IV patients (P <.001). In the 71 subjects who were not receiving 
      diuretic treatment, urinary ET-1 was selected as the strongest predictor of 
      sodium excretion by multivariate stepwise analysis. CONCLUSIONS: Urinary ET-1 
      excretion increases in an earlier phase of HF than plasma ET-1 and appears to be 
      closely correlated with sodium excretion, indicating renal ET-1 is a target for 
      ET-1 antagonists in patients with HF.
FAU - Modesti, P A
AU  - Modesti PA
AD  - Clinica Medica Generale e Cardiologia, University of Florence, Italy. 
      pamodesti@dfe.unifi.it
FAU - Cecioni, I
AU  - Cecioni I
FAU - Costoli, A
AU  - Costoli A
FAU - Poggesi, L
AU  - Poggesi L
FAU - Galanti, G
AU  - Galanti G
FAU - Serneri, G G
AU  - Serneri GG
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - United States
TA  - Am Heart J
JT  - American heart journal
JID - 0370465
RN  - 0 (Biomarkers)
RN  - 0 (Endothelin-1)
RN  - 113-79-1 (Arginine Vasopressin)
RN  - 114471-18-0 (Natriuretic Peptide, Brain)
RN  - 85637-73-6 (Atrial Natriuretic Factor)
RN  - 9NEZ333N27 (Sodium)
RN  - EC 3.4.23.15 (Renin)
SB  - IM
MH  - Aged
MH  - Arginine Vasopressin/blood
MH  - Atrial Natriuretic Factor/blood
MH  - Biomarkers/blood/urine
MH  - Circadian Rhythm
MH  - Disease Progression
MH  - Endothelin-1/blood/*urine
MH  - Female
MH  - Heart Failure/mortality/physiopathology/*urine
MH  - Hemodynamics/physiology
MH  - Humans
MH  - Kidney/*metabolism
MH  - Male
MH  - Middle Aged
MH  - Natriuretic Peptide, Brain/blood
MH  - Prognosis
MH  - Radioimmunoassay
MH  - Renin/blood
MH  - Severity of Illness Index
MH  - Sodium/*urine
MH  - Survival Rate
EDAT- 2000/09/30 11:00
MHDA- 2001/02/28 10:01
CRDT- 2000/09/30 11:00
PHST- 2000/09/30 11:00 [pubmed]
PHST- 2001/02/28 10:01 [medline]
PHST- 2000/09/30 11:00 [entrez]
AID - S0002-8703(00)84254-4 [pii]
AID - 10.1067/mhj.2000.109917 [doi]
PST - ppublish
SO  - Am Heart J. 2000 Oct;140(4):617-22. doi: 10.1067/mhj.2000.109917.